Souvenaid Ingredients

Learn about the combination of nutrients in Souvenaid and how this supports memory function.

Decorative image of molecules as a representation of ingredients

What is in Souvenaid®? 

Souvenaid® is a medical drink proven to nutritionally support memory function in the early stages of Alzheimer’s disease including mild cognitive impairment, backed by 20 years of research1-3. Souvenaid® is powered by Fortaysn connect, a unique combination of nutrients formulated to support the growth of brain connections4.

Souvenaid® Liquid & Souvenaid® Powder

Souvenaid® is available as both a liquid and powder. Souvenaid® Liquid is available in 3 flavours and comes as a 125ml bottle. The liquid flavours are strawberry, cappuccino and vanilla. Souvenaid® Powder comes as a 360g tin. Souvenaid® powder is available in 2 flavours; vanilla & banana and orange & lemon. Souvenaid® is best served chilled.

Souvenaid® Liquid is suited for those who want the ease of a ready to drink option. The powder is perfect for travelling or if storage space is an issue. Having both options on-hand at home can provide lots of variety and flexibility.

The key nutrients in Souvenaid®’s Fortasyn Connect are:

  • Uridine 5’-monophosphate
  • Choline
  • Omega-3 fatty acids
  • Phospholipids
  • Vitamins and Minerals: Souvenaid® contains a range of vitamins and minerals including vitamin C, vitamin E, selenium, vitamin B6, vitamin B12, and folic acid.
How do these nutrients help with early Alzheimer’s disease?

Early Alzheimer’s disease is characterised by a loss of brain connections (synapses) and cells (neurons). In a healthy brain these connections are critical for the formation of memory, learning and personality. In Alzheimer’s disease, neurons become damaged and their ability to send messages via these connections becomes impaired5.

In a healthy brain, formation of neurons and synapses is supported with a healthy varied diet. However there is evidence that people with early Alzheimer’s disease including MCI often have low levels of some key nutrients 6.

Souvenaid® is a medical drink proven to nutritionally support memory function in the early stages of Alzheimer’s disease. Souvenaid® is powered by Fortasyn Connect, a unique combination of nutrients formulated to support synapse formation. Souvenaid® has been studied in multiple clinical trials with over 20 years of research1-3.

Souvenaid is proven to slow memory and cognitive decline by an average of 60% in an early stage of Alzheimer’s disease known as mild cognitive impairment when taken daily for 3 years. Individual results may vary.3

Diagram showing where the billions of neurons live and the trillions of synapses occur.
Can Souvenaid® be used with medication for Alzheimer’s disease?

Souvenaid® should be safe and tolerated when taken in combination with Alzheimer’s disease medication7 but speak to your healthcare professional if you are taking any other medication.

The above is not intended to be a substitute for medical advice. Always seek health advice from your healthcare professional.

Souvenaid® is a Food for Special Medical Purpose (FSMP) for the dietary management of early Alzheimer’s disease. Must be used under medical supervision. Souvenaid® does not cure or alleviate Alzheimer’s disease.


  1. S Scheltens P et al. Efficacy of a medical food in mild Alzheimer’s disease: A randomized, controlled trial. Alzheimers Dement 2010; 6(1): 1–10.e1.
  2. Scheltens P et al. Efficacy of Souvenaid in mild Alzheimer’s disease: results from a randomized, controlled trial. J Alzheimers Dis 2012; 31(1): 225–36.
  3. Soininen H, et al. 36- month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer’s disease. Alzheimer’s Dement. 2021; 17:29-40
  4. Van Wijk N, et al. Targeting synaptic dysfunction in alzheimer’s disease by administering specific nutrient combination. Journal of Alzheimer’s disease. 2014;38:459-479.
  5. Dementia Australia. 2024 About Dementia/Alzheimer’s Disease. Available onlineAlzheimer’s disease | Dementia Australia
  6. de Wilde MC et al. Lower brain and blood nutrient status in Alzheimer’s disease: Results from meta-analyses. Alzheimers Dement (NY) 2017 Jun;24. doi: 10.1016/j.trci.2017.06.002.
  7. Shah RC, et al. The S-connect study: results from a randomized controlled trial of Souvenaid in mild to moderation Alzheimer’s disease. Alzheimer’s Research and Therapy. 2013; 5:59.
Was this helpful?
0 0